Rolland-Cachera M.F.,University of Paris 13 |
Maillot M.,Aix - Marseille University |
Maillot M.,French Institute of Health and Medical Research |
Deheeger M.,University of Paris 13 |
And 6 more authors.
International Journal of Obesity | Year: 2013
Background: There is overwhelming evidence that experiences during early life could have long-term health consequences. However, the role of early nutrition in programming obesity and leptin resistance is still poorly understood.Objective: We aimed at determining whether nutritional intakes in early life are associated with body composition and hormonal status at 20 years. Subjects: Healthy infants participating in the two-decade-long prospective ELANCE (Etude Longitudinale Alimentation Nutrition Croissance des Enfants) study were examined at 10 months and 2 years. At 20 years, weight, height, subscapular and triceps skinfold thicknesses, fat mass (FM) and fat-free mass (FFM) assessed via bioelectrical impedance analysis, and serum leptin concentration were recorded in 73 subjects still participating in the follow-up. Results: In adjusted linear regression models, an increase by 100 kcal in energy intake at 2 years was associated with higher subscapular skinfold thickness (β=6.4% SF, 95% confidence interval 2.53-10.30, P=0.002) and higher FFM (0.50 kg, 0.06-0.95, P=0.03) at 20 years. An increase by 1% energy from fat at 2 years was associated with lower subscapular skinfold thickness (-2.3% SF,-4.41 to-0.18, P=0.03), lower FM (-0.31 kg,-0.60 to-0.01, P=0.04) and lower serum leptin concentration (-0.21 μg l-1,-0.39 to-0.03, P=0.02) at 20 years. Conclusions: Low-fat intake in early life was negatively associated with body fat (particularly at the trunk site) and serum leptin concentration at 20 years, suggesting that early low-fat intake could increase the susceptibility to develop overweight and leptin resistance at later ages. These findings substantiate current recommendations against restricting fat intake in early life and open new directions for investigating the origin of obesity. © 2013 Macmillan Publishers Limited.
Cavalier E.,University of Liege |
Fache W.,Zuidstationstraat |
Souberbielle J.-C.,Laboratoire Dexplorations Fonctionnelles
International Journal of Endocrinology | Year: 2013
Vitamin D (VTD) treatment is recommended in patients presenting different causes of diseases. To treat these patients, physicians rely on the different available pharmaceutical forms present in their country. Unfortunately, even in a given country, there is no consensus on the best way to treat the patients. In Belgium, VTD is mostly prescribed as ampoules containing 25,000 IU of VTD. In this randomised controlled study, we evaluated whether four therapeutic schemes using multiples of 25,000 IU of VTD according to basal vitamin D concentration were able to increase or maintain the 25(OH)D serum level above 30 ng/mL. We randomized 175 subjects who received the drug (n=140) or placebo (n=35). Total duration of the study was 12 weeks. Doses ranged from 4167 to 1667 IU/day. Blood sampling was performed at baseline and each 4 visits. In the treated (placebo) subjects, mean 25(OH)D serum concentration was 18.7 (19.1) ng/mL at baseline and 31.5 (20.7) ng/mL at w-12. At the end of the study, 57.1% of the subjects treated with VTD presented 25(OH)D serum concentration ≥30 ng/mL, whereas 94.3% were ≥20 ng/mL. In conclusion, the doses administered were safe and increased or maintained the 25(OH)D concentration ≥20 ng/mL. However, concentrations ≥30 ng/mL were only achieved in 57.1% of the subjects. © 2013 Etienne Cavalier et al.
Bonjour J.-P.,University of Geneva |
Benoit V.,Collaborating Center for Osteoporosis Prevention |
Pourchaire O.,Yoplait |
Rousseau B.,Collaborating Center for Osteoporosis Prevention |
And 2 more authors.
Journal of Nutrition, Health and Aging | Year: 2011
Background: Nutritional approach to the deterioration of bone integrity and increased fracture risk appears to be particularly appropriate in elderly women living in nursing homes. Objective: To investigate the beneficial effect of the consumption of soft plain cheese on bone resorption markers in institutionalized elderly women. Design: Prospective, randomized crossover controlled study. Setting: Six French nursing homes or other institutions for elderly. Participants: Institutionalized women ≥ 65 years old with low vitamin D status and calcium intake below 700 mg/day. Intervention: Consumption of soft plain cheese made of semi-skimmed milk which was fortified by both vitamin D3 (+ 1.25μg/100g) and milk extracted Ca, thus achieving a total Ca content of 151 mg/100g as compared to about 118 mg/100g for standard fresh cheese. Two servings were taken every day during the 6 weeks that preceded or followed a period of 6 weeks without soft plain cheese consumption. Measurements: The primary end point was the change in serum carboxy terminal cross-linked telopeptide of type I collagen (CTX) selected as a marker of bone resorption. Results: 29 women aged 73-94 yr were selected, 21 of them with mean age 87.2±6.1 years remained compliant The intervention increased calcium and protein intakes by 51% (904±228 vs. 599±122 mg/d) and 33 % (74.2±17.1 vs. 55.6±12.7 g/d, mean±SD), respectively. The dietary intervention was associated with a statistically significant increase in serum levels of both 25OHD and IGF-I, while those of PTH, CTX and TRAP5b were significantly reduced. Compliance was 93,4 %. The daily consumption of two servings of soft plain cheese was well accepted in terms of tastiness and appetite suited portion size. Conclusion: This randomized crossover controlled trial demonstrates that in elderly women living in nursing homes, the consumption of soft plain cheese increasing the supply of vitamin D, calcium and proteins, could reduce bone resorption and thereby reduce the risk of incidental fragility fractures in the long term. © 2011 Serdi and Springer Verlag France.
Delvin E.,McGill University |
Delvin E.,University of Montreal |
Souberbielle J.-C.,Laboratoire Dexplorations Fonctionnelles |
Viard J.-P.,UF de Therapeutique en Immuno infectiologie |
Salle B.,University of Lyon
Critical Reviews in Clinical Laboratory Sciences | Year: 2014
Vitamin D has been attributed roles in the pathogenesis and prevention of several diseases such as cancer, cardiovascular disease, multiple sclerosis, diabetes, autism and autoimmune diseases. The concomitant expression of the 25-hydroxyvitamin D3-1α-hydroxylase and of the vitamin D3 receptor in animal and human tissues and organs other than bone supports this paradigm. Translated into the clinical field, meta-analyses and systematic reviews have also revealed an association between vitamin D insufficiency or deficiency and non-osseous diseases. Although relying on the large databases, they are diverse in nature and involve participants of varying age and evolving in different environments. Furthermore, they do not allow any analysis of a possible causal relationship between vitamin D supplementation and clinical outcomes. Following a brief historical account, this review addresses these caveats, and gives examples of randomized controlled trials conducted in the fields of acquired immune and autoimmune diseases. © 2014 Informa Healthcare USA, Inc.
Cavalier E.,University of Liege |
Carlisi A.,University of Liege |
Bekaert A.-C.,University of Liege |
Rousselle O.,University of Liege |
And 2 more authors.
Clinical Biochemistry | Year: 2012
Objectives: Validation of the Architect 25-OH vitamin D assay. Design and methods: Determination of repeatability, reproducibility, accuracy profile and 25(OH)-vitamin D2 recovery on native samples. Comparison with DiaSorin Liaison and RIA. Results and conclusion: Coefficients of variation: < 6% (13.6. ng/mL) and 2.2% (78.1. ng/mL). Functional sensitivity: 5. ng/mL. Accuracy profile shows that the method is validated between 13.6 and 78.1. ng/mL. Recovery of 25(OH)D2: 75,8%( 95% CI: 61.9-89.7%). Good correlation with DiaSorin RIA and Liaison < 50. ng/mL; above this threshold a systematic positive bias was observed. © 2012 The Canadian Society of Clinical Chemists.